Genentech unveils pivotal neuroimmunology Phase III data at MSToronto2026

Conference coverage

Genentech presented new Phase III data across more than 40 abstracts at MSToronto2026, including late-breaking fenebrutinib results and a "Best of MSToronto2026" Enspryng presentation.

Fenebrutinib pivotal Phase III findings

Pivotal trials in relapsing (FENhance 1 & 2) and primary progressive (FENtrepid) MS show fenebrutinib reduced slowly expanding lesion (SEL) volume up to 30% (RMS 96 weeks; PPMS 120 weeks) and decreased paramagnetic rim lesion (PRL) accumulation by 62% in RMS versus active comparators. In pooled RMS analyses, 75% of fenebrutinib-treated patients achieved no evidence of disease activity (NEDA-3), and annualized relapse rate (ARR) fell 55% over 96 weeks versus comparator. Additional findings include 23% lower annual total brain volume loss and a 16% reduction in 12-week composite confirmed disability progression.

Ocrevus across ages

OPERETTA 2 pediatric data show 90% of participants aged 10–17 remained relapse-free over two years. Analyses reported selective B‑cell depletion with preservation of other immune cells and maintained pre-existing vaccine immunity in most patients. In adults >55, 53% showed no disability progression at two years, similar to younger cohorts.

Enspryng in MOGAD

Exploratory METEOROID analyses indicate Enspryng reduced relapse risk and was associated with numerically superior recovery at 12 weeks post-relapse (median EDSS change -2 vs -0.5 versus placebo), supporting its potential in MOGAD; an FDA decision is expected in January 2027.